Kliniken Essen-Mitte,Evangelische Huyssens-Stiftung

At Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, a major share of the clinical research focuses on breast cancer across early, locally advanced, and metastatic disease. Studies in this area explore HER2-positive, hormone receptor-positive, and triple-negative breast cancer, with the goal of improving treatment effectiveness, reducing recurrence, and refining perioperative and maintenance strategies.

• Testing new targeted and immune-based therapies for HER2-positive breast cancer
• Evaluating treatment options for triple-negative breast cancer and high-risk disease
• Studying endocrine and pathway-directed approaches in HR-positive/HER2-negative breast cancer

Research in the Klinik für Senologie/ Brustzentrum also includes efforts to improve early detection, predict response to therapy, and lower the risk of relapse after surgery.

This site is also active in gynecologic cancer research, especially for ovarian cancer, endometrial cancer, cervical cancer, and related rare tumors. The trials aim to improve outcomes for patients with advanced, recurrent, or treatment-resistant disease by testing new therapies and better maintenance approaches.

• Investigating treatment strategies for platinum-resistant and platinum-sensitive ovarian cancer
• Studying therapies for endometrial cancer and high-risk postoperative disease
• Evaluating options for cervical cancer and other recurrent gynecologic malignancies

Several studies focus on extending disease control, improving survival, and supporting more personalized care for women with advanced gynecologic malignancies.

Clinical trials in respiratory tract diseases center on non-small cell lung cancer, small-cell lung cancer, and selected metastatic lung tumors. The research is designed to compare new immunotherapies, targeted treatments, and combination regimens with standard care in both untreated and previously treated disease.

• Evaluating immunotherapy combinations for non-small cell lung cancer
• Studying targeted options for mutation-defined disease such as KRAS G12C and BRAF-V600
• Assessing treatment effectiveness in advanced and metastatic lung cancer

These studies aim to improve survival, delay progression, and expand options for patients with hard-to-treat thoracic cancers.

Another important area of research involves digestive system diseases, especially colorectal cancer, gastric cancer, and esophagogastric adenocarcinoma. The trials are focused on testing new drug combinations and improving treatment after surgery or in metastatic settings.

• Studying therapies for metastatic colorectal cancer and locally advanced rectal disease
• Evaluating treatment approaches for gastric and gastroesophageal junction cancers
• Assessing new options for advanced esophagogastric adenocarcinoma

Research here aims to improve disease control, support postoperative recovery, and identify more effective treatments for advanced gastrointestinal cancers.

The site also contributes to studies in male urogenital diseases, bladder cancer, and prostate cancer, as well as cancers influenced by hormonal pathways. These trials are designed to evaluate whether newer therapies can improve outcomes in both localized and metastatic disease.

• Investigating treatment strategies for muscle-invasive and high-risk urothelial carcinoma
• Studying systemic therapy for prostate cancer
• Exploring hormone- and pathway-based approaches in selected hormone-driven cancers

Overall, this research seeks to improve tumor control, reduce recurrence, and broaden treatment choices for patients with urogenital malignancies.

Beyond the main disease groups, the portfolio includes studies in solid tumors, neoplasms, and selected supportive care topics. These trials often examine whether new therapies can improve quality of life, help control symptoms, or provide better long-term disease management.

• Testing novel treatments across advanced solid tumors
• Evaluating symptom-focused research such as cancer cachexia and treatment-related effects
• Studying supportive care questions, including recovery after gastrectomy

This broader work complements the site’s cancer-focused research by addressing both treatment effectiveness and patient well-being.